structural cardiac disease
structural heart disease Patients
Activation of cardiac
prevalent disease
placebo-controlled trial of mirabegron
diastolic function
cardiac MRI
human receptor
clinical trial
myocardial hypertrophy
B3AR expression
diastolic ventricular function
overactive bladder disease
cardiovascular risk factors
risk of developing heart failure
new agonist of B3AR available
new beta3-adrenergic receptor agonist
overt heart failure
HFpEF
standard treatment of patients
new concept
control of risk factors
additional beneficial effect of mirabegron
myocardial remodelling
human use
pre-clinical discoveries
myocardial remodeling
pre-clinical models
human myocardium
brown fat activation
vascular Beta3-adrenergic receptors
defined treatment
multi-center
primary objective
left ventricular mass
non-cardiovascular indication
major conceptual advance
major health problem
co-primary end-point
preserved ejection fraction
classification
context
beige
obesity
novel target
original drug
stage B
Doppler echocardiography
response
neurohormonal
fibrosis
quantitative change
hypertension
exercise tolerance
peak VO2
metabolism
elderly
coupling
months
hemodynamic stress
circulating biomarkers
proposal
women population
project
vasculature